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Interleukin-6 (IL-6) is known to promote tumour growth and survival. We evaluated IL-6 gene amplification in tumours from 53
glioma patients using fluorescence in situ hybridisation. Amplification events were detected only in glioblastomas (15 out of 36 cases),
the most malignant tumours, and were significantly associated with decreased patient survival.
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INTRODUCTION
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates the
immune response, but also plays a role in promoting tumour
growth and survival (Trikha et al, 2003; Hodge et al, 2005). In
gliomas, the level of IL-6 gene expression increases with the grade
of malignancy (Rolhion et al, 2001). In glioblastoma multiforme
(GBM), the most malignant glioma, amplification/overexpression
of the IL-6 gene appears to be a common feature (Tchirkov et al,
2001). Recent genomic array studies have reported that the
number of IL-6 gene copies was increased in 40–50% of GBM
(Suzuki et al, 2004; Saigusa et al, 2005). It is however unknown
whether this alteration could be found in gliomas of lower
malignancy grades. The prognostic significance of IL-6
gene amplification in GBM has not yet been determined. To
address these issues, we evaluated here IL-6 gene amplification
using interphase fluorescence in situ hybridisation (FISH) in 53
gliomas representative of various histological types and malig-
nancy grades. In GBM, the results were correlated with patient
survival.
MATERIALS AND METHODS
Glioma samples were taken from the material of surgical resection
during the course of standard diagnostic procedure. Histological
diagnosis and grading of tumours was consistent with the World
Health Organization (WHO) criteria (World Health Organization,
2000). Nine tumours were classified as low-grade gliomas (grade
I–II), including one pilocytic astrocytoma, three astrocytomas,
two oligodendrogliomas and three oligoastrocytomas. Eight
tumours were anaplastic gliomas (grade III), including six
anaplastic oligoastrocytomas and two anaplastic oligodendroglio-
mas. The remaining 36 tumours were classified as GBM (grade IV).
Patients with malignant gliomas (grade III–IV) were treated by
surgery followed by either high-dose carmustine followed by
radiotherapy in cases with optimal tumour resection or radio-
therapy and concomitant temozolomide followed by monthly
cycles of adjuvant temozolomide in cases with partial tumour
resection or biopsy alone.
An interphase FISH was performed on frozen sections of
gliomas mounted on Fisher Superfrost slides. The IL-6 gene probe
was designed from the bacterial artificial chromosome clone RP11-
240H8 (GenBank Accession Number AC073072) kindly provided
by Professor Mariano Rocchi (University of Bari, Italy). The IL-6
probe labelled with SpectrumGreen (Vysis/Abbott, Rungis, France)
and chromosome 7 cetromeric probe labelled with Spectrum-
Orange (Vysis/Abbott) were co-hybridised to evaluate simulta-
neously the number of IL-6 gene and chromosome 7 copies. A
median of 148 nuclei (116–245, interquartile range) was scored
using a Metafer4-MetaCyte microscope scanning system (Meta-
Systems, Le Cannet, France).
The number of IL-6 mRNA transcripts was assessed using
quantitative real-time reverse transcriptase-PCR (qRT–PCR) in
the LightCycler system (Roche Diagnostics, Meylan, France) with
IL-6 specific primers (Tchirkov et al, 2001) and normalised to the
expression of a housekeeping gene, ABL (Tchirkov et al, 2003).
Analyses of statistical links between biological and clinical
characteristics were performed using standard tests. Overall
survival was calculated using the Kaplan–Meier method and
survival curves were compared using the log-rank test. A
multivariate analysis was performed using the Cox regression
model.
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Using interphase FISH approach, no IL-6 gene amplification was
detected in low-grade or anaplastic tumours (n¼17), whereas
high-level amplification was found in 15 out of 36 (41.7%) GBM
(Figure 1A and B). The percentage of nuclei with amplification
events varied between 21 and 77% (33%, median).
Quantification of IL-6 mRNA with qRT–PCR revealed a highly
significant increase in the mean IL-6/ABL ratio in GBM (33.3%) as
compared with non-GBM (1.5%; Kruskal–Wallis test,
P¼3.8 10
 6). The mean IL-6/ABL ratio was 410-fold greater
in GBM manifesting IL-6 gene amplification than in GBM without
amplification (71.6 vs 6.1%; P¼4.3 10
 7).
GBM patients with amplified IL-6 gene had significantly shorter
survival than patients without amplification (log-rank test,
P¼0.0000073; Figure 1C). Multivariate Cox analysis for overall
survival, including IL-6 amplification, extent of tumour resection
and age as variables, demonstrated that IL-6 amplification was an
independent factor of poor prognosis (relative risk (RR) amplified
vs non-amplified 8.07; P¼0.000016). The complete tumour
resection, equally distributed among patients with and without
IL-6 gene amplification, was an independent factor of favourable
prognosis (RR complete vs partial 0.31; P¼0.013). Age did not
influence survival of patients.
DISCUSSION
Glioblastomas are the most devastating primary brain
tumours. Despite modern treatments, about 40% of patients
with GBM die within 6 months after diagnosis (Reardon et al,
2006). In the present study, we demonstrated that one of the
molecular abnormalities associated with the aggressiveness of
GBM is the amplification of the IL-6 gene, which was found in
41.7% of patients and significantly correlated with decreased
survival.
Amplifications on chromosome 7p in GBM are believed
to be driven by the amplification of the epidermal growth
factor receptor (EGFR) gene locus (Rossi et al, 2005). This
initial amplification event may induce instability along the
length of this chromosomal arm, resulting in co-amplification
of other genes. Of note, EGFR gene amplification has no clear
prognostic value in GBM (Houillier et al, 2006). It may be possible
that some of co-amplified (or independently amplified) genes are
involved in glioma development and progression and are
important for patient prognosis. Novel amplicons on chromosome
7p distinct from EGFR were recently identified using high-
resolution genomic analyses and were reported to contain, among
other genes, the IL-6 gene that was overexpressed (Rossi et al,
2005).
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Figure 1 (A and B) Example of FISH analysis of chromosome 7 (red signals) and IL-6 gene (green signals) copy numbers in frozen sections of glioma
tumours. A nucleus showing two copies of chromosome 7 and two copies of IL-6 gene (A); a nucleus with two copies of chromosome 7 and a high-level
amplification of IL-6 gene (ratio of IL-6 to centromere 7 signals greater than 3) (B). (C) Overall survival as a function of IL-6 gene status in GBM patients.
Patients with IL-6 gene amplification had significantly shorter survival than patients without amplification.
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(Goswami et al, 1998) and angiogenesis (Loeffler et al, 2005). This
cytokine also protects cancer cells from apoptotic depletion during
chemotherapy and radiotherapy through activation of the Janus
kinase/STAT and phosphatidylinositol 3-kinase/AKT pathways
(Miyamoto et al, 2001; Trikha et al, 2003; Hodge et al, 2005). In
this context, amplification of the IL-6 gene leading to its
overexpression is likely one of the major factors contributing to
the aggressiveness and poor response to therapies of GBM. It may
therefore be suggested that targeting IL-6 and its signalling
pathways in GBM would sensitise these otherwise resistant
tumours to chemotherapeutic drugs and radiotherapy.
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